The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Long-Term Evaluation of a Phase 1 Study of AADC Gene Therapy for Parkinson's Disease
Open accessAbstract
We report the results of a long-term follow-up of subjects in a phase 1 study of AAV2-hAADC (adeno-associated virus type 2–human aromatic L-amino acid decarboxylase) gene therapy for the treatment of Parkinson's disease (PD). Ten patients with moderately advanced PD received bilateral putaminal infusions of either a low or a high dose of AAV2-hAADC vector. An annual positron emission tomography (PET) imaging with [18F]fluoro-L-m-tyrosine tracer was used for evaluation of AADC expression, and a standard clinical rating scale [Unified Parkinson's Disease Rating Scale (UPDRS)] was used to assess effect. Our previous analysis of the 6-month data suggested that this treatment was acutely safe and well tolerated. We found that the elevated PET signal observed in the first 12 months persisted over 4 years in both dose groups. A significantly increased PET value compared with the presurgery baseline was maintained over the 4-year monitoring period. The UPDRS in all patients off medication for 12 hr improved in the first 12 months, but displayed a slow deterioration in subsequent years. This analysis demonstrates that apparent efficacy continues through later years with an acceptable safety profile. These data indicate stable transgene expression over 4 years after vector delivery and continued safety, but emphasize the need for a controlled efficacy trial and the use of a higher vector dose. Mittermeyer and colleagues report results from a phase 1 study of AAV2-hAADC (human aromatic l-amino acid decarboxylase) gene therapy for the treatment of Parkinson's disease. The study shows that AAV2-hAADC treatment was safe and that AADC gene expression was maintained at least 4 years after administration of therapy. Positron emission tomography analysis showed that a similar number of neurons continued expressing the transgene throughout the study.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Marks, W. J., Bartus, R. T., Siffert, J., Davis, C. S., Lozano, A., Boulis, N., Vitek, J., Stacy, M., Turner, D., Verhagen, L., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70254-4 · Cited by 684
Self-citationSafety and tolerability of putaminal AADC gene therapy for Parkinson disease
Christine, C. W., Starr, P. A., Larson, P. S., Eberling, J. L., Jagust, W. J., Hawkins, R. A., VanBrocklin, H. F., Wright, J. F., Bankiewicz, K. S., & Aminoff, M. J. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c29356 · Cited by 445
Self-citationBankiewicz, K. S., Eberling, J. L., Kohutnicka, M., Jagust, W., Pivirotto, P., Bringas, J., Cunningham, J., Budinger, T. F., & Harvey-White, J. (2000) · Experimental Neurology · doi:10.1006/exnr.2000.7408 · Cited by 406
Self-citationResults from a phase I safety trial of hAADC gene therapy for Parkinson disease
Eberling, J. L., Jagust, W. J., Christine, C. W., Starr, P., Larson, P., Bankiewicz, K. S., & Aminoff, M. J. (2008) · Neurology · doi:10.1212/01.wnl.0000312381.29287.ff · Cited by 370
Self-citationLong-Term Clinical Improvement in MPTP-Lesioned Primates after Gene Therapy with AAV-hAADC
Bankiewicz, K. S., Forsayeth, J., Eberling, J. L., Sanchez-Pernaute, R., Pivirotto, P., Bringas, J., Herscovitch, P., Carson, R. E., Eckelman, W., Reutter, B., et al. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.05.005 · Cited by 282
Self-citationThe placebo effect in Parkinson's disease
de la Fuente-Fernández, R. (2002) · Trends in Neurosciences · doi:10.1016/s0166-2236(02)02181-1 · Cited by 187
Biochemistry of postmortem brains in Parkinson’s disease: historical overview and future prospects
Nagatsu, T., & Sawada, M. (2007) · Neuropsychiatric Disorders An Integrative Approach · doi:10.1007/978-3-211-73574-9_14 · Cited by 184
Gross, R. E., Watts, R. L., Hauser, R. A., Bakay, R. A., Reichmann, H., von Kummer, R., Ondo, W. G., Reissig, E., Eisner, W., Steiner-Schulze, H., et al. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70097-7 · Cited by 159
Eight Years of Clinical Improvement in MPTP-Lesioned Primates After Gene Therapy With AAV2-hAADC
Hadaczek, P., Eberling, J. L., Pivirotto, P., Bringas, J., Forsayeth, J., & Bankiewicz, K. S. (2010) · Molecular Therapy · doi:10.1038/mt.2010.106 · Cited by 158
Self-citationvan Hilten, J. J., van der Zwan, A. D., Zwinderman, A. H., & Roos, R. A. C. (1994) · Movement Disorders · doi:10.1002/mds.870090113 · Cited by 136
O’Sullivan, J. D., Said, C. M., Dillon, L., Hoffman, M., & Hughes, A. J. (1998) · Movement Disorders · doi:10.1002/mds.870130607 · Cited by 121
Ichinose, H., Ohye, T., Fujita, K., Pantucek, F., Lange, K., Riederer, P., & Nagatsu, T. (1994) · Journal of Neural Transmission - Parkinson's Disease and Dementia Section · doi:10.1007/bf02250926 · Cited by 107
Richardson, R. M., Kells, A. P., Martin, A. J., Larson, P., Starr, P. A., Piferi, P., Bates, G., Tansey, L., Rosenbluth, K. H., Bringas, J. R., et al. (2011) · Stereotactic and Functional Neurosurgery · doi:10.1159/000323544 · Cited by 104
Self-citationA Dose-Ranging Study of AAV-hAADC Therapy in Parkinsonian Monkeys
Forsayeth, J., Eberling, J. L., Sanftner, L. M., Zhen, Z., Pivirotto, P., Bringas, J., Cunningham, J., & Bankiewicz, K. S. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.04.008 · Cited by 103
Self-citationStriatal volume differences between non-human and human primates
Yin, D., Valles, F. E., Fiandaca, M. S., Forsayeth, J., Larson, P., Starr, P. A., & Bankiewicz, K. S. (2008) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2008.08.027 · Cited by 95
Self-citationCunningham, J., Pivirotto, P., Bringas, J., Suzuki, B. M., Vijay, S., Sanftner, L. M., Kitamura, M., Chan, C. M., & Bankiewicz, K. S. (2008) · Molecular Therapy · doi:10.1038/mt.2008.111 · Cited by 73
Self-citationValles, F. E., Fiandaca, M. S., Eberling, J. L., Starr, P. A., Larson, P., Christine, C. W., Forsayeth, J., Richardson, R. M., Su, X., Aminoff, M. J., et al. (2010) · Neurosurgery · doi:10.1227/neu.0b013e3181f53a5c · Cited by 72
Self-citationT2 imaging in monitoring of intraparenchymal real-time convection-enhanced delivery
Richardson, R. M., Gimenez, F., Salegio, E. A., Su, X., Bringas, J., Berger, M. S., & Bankiewicz, K. S. (2011) · Neurosurgery · doi:10.1227/neu.0b013e318217217e · Cited by 38
Self-citationSubregional 6-[18F]fluoro-ʟ-m-tyrosine Uptake in the Striatum in Parkinson's Disease
Asari, S., Fujimoto, K., Miyauchi, A., Satō, T., Nakano, I., & Muramatsu, S. (2011) · BMC Neurology · doi:10.1186/1471-2377-11-35 · Cited by 21
Gene therapy for Parkinson’s disease: where are we now and where are we going?
Forsayeth, J., Bankiewicz, K. S., & Aminoff, M. J. (2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.10.161 · Cited by 13
Self-citation
Cited by
Poewe, W., Seppi, K., Tanner, C. M., Halliday, G. M., Brundin, P., Volkmann, J., Schrag, A.-E., & Lang, A. E. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.13 · Cited by 5,415
Palfi, S., Gurruchaga, J. M., Ralph, G. S., Lepetit, H., Lavisse, S., Buttery, P. C., Watts, C., Miskin, J., Kelleher, M., Deeley, S., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61939-x · Cited by 450
Lang, A. E., & Espay, A. J. (2018) · Movement Disorders · doi:10.1002/mds.27360 · Cited by 370
Various AAV Serotypes and Their Applications in Gene Therapy: An Overview
Issa, S. S., Shaimardanova, A. A., Solovyeva, V. V., & Rizvanov, A. A. (2023) · Cells · doi:10.3390/cells12050785 · Cited by 313
Gene therapy for neurological disorders: progress and prospects
Deverman, B. E., Ravina, B. M., Bankiewicz, K. S., Paul, S. M., & Sah, D. W. Y. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.110 · Cited by 306
Self-citation
Metadata
- Authors
- Mittermeyer, G., Christine, C. W., Rosenbluth, K. H., Baker, S. L., Starr, P., Larson, P., Kaplan, P. L., Forsayeth, J., Aminoff, M. J., & Bankiewicz, K. S.
- Venue
- Human Gene Therapy
- Publisher
- SAGE Publications
- Published
- 2012-04
- Volume
- 23
- Issue
- 4
- Pages
- 377-381
- ISSN
- 1043-0342 (ISSN-L)
- 1557-7422
- OpenAlex
- W2065259720
- Cited by
- 298
- References
- 20
- FWCI
- 12.22
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.